| J9271 | Injection, pembrolizumab, 1 mg | 12,600 | $40 | $541.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 910 | $90 | $79.6K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 2,640 | $30 | $66K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 4,100 | $20 | $65.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 350 | $120 | $43K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 410 | $100 | $39.6K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 310 | $80 | $25.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 280 | $90 | $25.5K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 130 | $130 | $16.9K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 190 | $90 | $16.7K |